 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Supportive Care – Anemia
| AMG 114 |
Hyperglycosylated analog of Aranesp® |
Amgen |
I/II |
| Dynepo (erythropoietin) |
Glycoprotein |
Transkaryotypic Therapies Aventis |
Application Submitted |
| Hemolink (hemoglobin raffimer) |
Hemoglobin therapeutic |
Hemosol |
II (Anemia) |
| R744 |
New generation epo |
Hoffman-LaRoche |
III |
| R1516 |
Synthetic erythropoietin |
Hoffman-LaRoche |
I |
| Velafermon CG53135 |
Protein growth factor |
Curagen |
I |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
